Structure determination of amyloid oligomers, the pathogenic species in Alzheimer ́s disease using fast MAS NMR and microfluidics

Información del proyecto

Oligomers-MAS-NMR

Identificador del acuerdo de subvención: 101038074

DOI

10.3030/101038074

Proyecto cerrado

Fecha de la firma de la CE 31 Marzo 2021

Fecha de inicio 1 Diciembre 2021

Fecha de finalización 30 Noviembre 2023

Financiado con arreglo a

• SPREADING EXCELLENCE AND WIDENING PARTICIPATION

Coste total

€ 140 202,24

Aportación de la UE

€ 140 202,24

Coordinado por

LATVIJAS ORGANISKAS SINTEZES INSTITUTS
Latvia

Periodic Reporting for period 1 - Oligomers-MAS-NMR (Structure determination of amyloid oligomers, the pathogenic species in Alzheimer ́s disease using fast MAS NMR and microfluidics)

Período documentado: 2021-12-01 hasta 2023-11-30

Resumen del contexto y de los objetivos generales del proyecto

Neurogenerative diseases (ND) are one of the major threats to an ever-aging society. Despite this, still no efficient drugs or vaccines are available. Previously, several oligomer and fibril forming proteins, where found in the brains of people who suffered from ND. Structural characterization at the atomic level of these aggregated particles would help to push the discovery of drugs and vaccine candidates against ND. Solid-state nuclear magnetic resonance spectroscopy (ssNMR) at magic angle spinning (MAS) has evolved as a powerful tool for structural biology, especially for proteins involved in ND. However, ssNMR still has a limitation of sensitivity and resolution for site-specific studies. During this project we will address this problem by exploring: (I) cell-free synthesis schemes for novel fluorine incorporation into protein aggregates. (II) engineering of microfluidic devices to prepare oligomeric shape particles. III. Fast MAS methods to detect fluorine and proton nucleus. A combination of these methods could help broaden the boundaries of MAS ssNMR spectroscopy to aid in the development of a new type of therapeutics against ND.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

We established a cost-efficient cell-free protein synthesis method in incorporate non-canonical fluorinated aliphatic amino acids. For ssNMR spectroscopy we explored in details coherent and incoherent contributions to fluorine line-widths at various MAS rates. At the moment, it was the first detailed research on this topic in the ssNMR community. We acquired a multidimensional ssNMR spectra and conducted chemical shift assignments of protein aggregates, enabling us to determine the secondary structural elements and compare it with the structures obtained by cry electron microscopy. We build a stable microfluidic device using cheap, in-house manufactured components.
The results achieved in this project were presented as oral or poster presentation in local (Riga in Latvia) and international conferences (Tallin in Estonia, Paris in France, IBCG at Boston in USA). These presentations approach a wide variety of scientist in the fields of protein biochemistry, amyloid proteins and ssNMR. This allowed us to establish new scientific collaborations in Europe.
For a general audience we presented our work in "shadowing days" for high-school students and “Researchers' night” at the hosting institute. Additionally lectures about protein biochemistry and ssNMR methods were presented for university students.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The scientific results achieved in this project showed the new possibilities of MAS ssNMR fluorine and proton detection methods in studying proteins associated with Alzheimer’s and Parkinson’s diseases. Our advances in protein cell-free synthesis have a potential to establish new biotechnological methods for protein engineering with unnatural amino acids. Both ssNMR spectroscopy and cell-free synthesis could be applied to study other challenging and large protein aggregates, uniquely contributing to the development of new therapeutics against ND.

graphical-abstract.png